You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 14, 2024

Investigational Drug Information for Ipatasertib

✉ Email this page to a colleague

« Back to Dashboard

What is the drug development status for Ipatasertib?

Ipatasertib is an investigational drug.

There have been 56 clinical trials for Ipatasertib. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2023.

The most common disease conditions in clinical trials are Breast Neoplasms, Triple Negative Breast Neoplasms, and Prostatic Neoplasms. The leading clinical trial sponsors are Hoffmann-La Roche, Genentech, Inc., and National Cancer Institute (NCI).

There are one hundred and twenty-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Ipatasertib
A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored StudyHoffmann-La RochePhase 4
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial CancersNational Cancer Institute (NCI)Phase 1/Phase 2
Study of Chemotherapy Plus Ipatasertib in Participants With Solid Tumors With AKT Mutations, A ComboMATCH Treatment TrialNational Cancer Institute (NCI)Phase 2

See all Ipatasertib clinical trials

Clinical Trial Summary for Ipatasertib

Top disease conditions for Ipatasertib
Top clinical trial sponsors for Ipatasertib

See all Ipatasertib clinical trials

US Patents for Ipatasertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Ipatasertib ⤷  Sign Up Substituted thiohydantoin derivatives as androgen receptor antagonists Janssen Pharmaceutica NV (Beerse, BE) ⤷  Sign Up
Ipatasertib ⤷  Sign Up Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC) ⤷  Sign Up
Ipatasertib ⤷  Sign Up Treatment of ophthalmic conditions by selectively removing senescent cells from the eye Unity Biotechnology, Inc. (Brisbane, CA) Buck Institute for Research on Aging (Novato, CA) Mayo Foundation for Medical Education and Research (Rochester, MN) ⤷  Sign Up
Ipatasertib ⤷  Sign Up Benzimidazole derivatives as bromodomain inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Sign Up
Ipatasertib ⤷  Sign Up Polymeric nanoparticles and methods of making and using same Merck Sharp & Dohme Corp. (Rahway, NJ) Pfizer Inc. (New York, NY) ⤷  Sign Up
Ipatasertib ⤷  Sign Up Heterocyclic estrogen receptor modulators and uses thereof Genentech, Inc. (South San Francisco, CA) ⤷  Sign Up
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Ipatasertib

Drugname Country Document Number Estimated Expiration Related US Patent
Ipatasertib Argentina AR107432 2036-01-11 ⤷  Sign Up
Ipatasertib Australia AU2017207268 2036-01-11 ⤷  Sign Up
Ipatasertib Australia AU2019203280 2036-01-11 ⤷  Sign Up
Ipatasertib Australia AU2021201018 2036-01-11 ⤷  Sign Up
Ipatasertib Brazil BR112018014015 2036-01-11 ⤷  Sign Up
Ipatasertib Canada CA3010509 2036-01-11 ⤷  Sign Up
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.